BACKGROUND: Ibrutinib is a Bruton tyrosine kinase inhibitor and is approved for the treatment of patients with chronic lymphocytic leukemia (CLL) in frontline and relapsed/refractory settings. The authors previously reported poor outcomes for patients who discontinued ibrutinib; however, long-term outcomes were not reported. METHODS: Data from 320 patients who received ibrutinib on clinical studies between 2010 and 2015 at The University of Texas MD Anderson Cancer Center were retrospectively analyzed. RESULTS: Long-term outcomes among patients with CLL after they discontinued ibrutinib were analyzed. Ninety of 320 patients (28%) who were treated on ibrutinib-based regimens discontinued ibrutinib. Of these, 80 had relapsed/refractory disease, and 10 were treatment-naive. The median time to discontinuation was 15 months (range, 1.2-54 months). After a median follow-up of 38 months after starting ibrutinib, 40 patients (44%) remained alive. Major reasons for ibrutinib discontinuation were intolerance (n = 29; 32%), miscellaneous (n = 28; 31%), progression (n = 19; 21%), and Richter transformation (RT) (n = 9; 10%). The median survival according to the reason for discontinuation was 33 months for ibrutinib intolerance, 11 months for miscellaneous causes, 16 months for progressive CLL, and 2 months for RT. Among the 19 patients who had progressive CLL, 42% responded to subsequent therapy. CONCLUSIONS: Ibrutinib discontinuation was observed during therapy. Patients with CLL who had disease transformation had especially poor outcomes, whereas those who developed progressive disease during ibrutinib therapy had a median survival of <1.5 years. Survival was associated with the reason for discontinuation; patients who had progressive CLL had better survival compared with those who had disease transformation. Effective salvage strategies for patients with CLL who progress on ibrutinib therapy is of critical importance. Cancer 2017;123:2268-2273.
BACKGROUND:Ibrutinib is a Bruton tyrosine kinase inhibitor and is approved for the treatment of patients with chronic lymphocytic leukemia (CLL) in frontline and relapsed/refractory settings. The authors previously reported poor outcomes for patients who discontinued ibrutinib; however, long-term outcomes were not reported. METHODS: Data from 320 patients who received ibrutinib on clinical studies between 2010 and 2015 at The University of Texas MD Anderson Cancer Center were retrospectively analyzed. RESULTS: Long-term outcomes among patients with CLL after they discontinued ibrutinib were analyzed. Ninety of 320 patients (28%) who were treated on ibrutinib-based regimens discontinued ibrutinib. Of these, 80 had relapsed/refractory disease, and 10 were treatment-naive. The median time to discontinuation was 15 months (range, 1.2-54 months). After a median follow-up of 38 months after starting ibrutinib, 40 patients (44%) remained alive. Major reasons for ibrutinib discontinuation were intolerance (n = 29; 32%), miscellaneous (n = 28; 31%), progression (n = 19; 21%), and Richter transformation (RT) (n = 9; 10%). The median survival according to the reason for discontinuation was 33 months for ibrutinib intolerance, 11 months for miscellaneous causes, 16 months for progressive CLL, and 2 months for RT. Among the 19 patients who had progressive CLL, 42% responded to subsequent therapy. CONCLUSIONS:Ibrutinib discontinuation was observed during therapy. Patients with CLL who had disease transformation had especially poor outcomes, whereas those who developed progressive disease during ibrutinib therapy had a median survival of <1.5 years. Survival was associated with the reason for discontinuation; patients who had progressive CLL had better survival compared with those who had disease transformation. Effective salvage strategies for patients with CLL who progress on ibrutinib therapy is of critical importance. Cancer 2017;123:2268-2273.
Authors: Jan A Burger; Michael J Keating; William G Wierda; Elena Hartmann; Julia Hoellenriegel; Nathalie Y Rosin; Iris de Weerdt; Ghayathri Jeyakumar; Alessandra Ferrajoli; Marylou Cardenas-Turanzas; Susan Lerner; Jeffrey L Jorgensen; Graciela M Nogueras-González; Gracy Zacharian; Xuelin Huang; Hagop Kantarjian; Naveen Garg; Andreas Rosenwald; Susan O'Brien Journal: Lancet Oncol Date: 2014-08-20 Impact factor: 41.316
Authors: Inhye E Ahn; Chingiz Underbayev; Adam Albitar; Sarah E M Herman; Xin Tian; Irina Maric; Diane C Arthur; Laura Wake; Stefania Pittaluga; Constance M Yuan; Maryalice Stetler-Stevenson; Susan Soto; Janet Valdez; Pia Nierman; Jennifer Lotter; Liqiang Xi; Mark Raffeld; Mohammed Farooqui; Maher Albitar; Adrian Wiestner Journal: Blood Date: 2017-01-03 Impact factor: 22.113
Authors: Anthony R Mato; Chadi Nabhan; Paul M Barr; Chaitra S Ujjani; Brian T Hill; Nicole Lamanna; Alan P Skarbnik; Christina Howlett; Jeffrey J Pu; Alison R Sehgal; Lauren E Strelec; Alexandra Vandegrift; Danielle M Fitzpatrick; Clive S Zent; Tatyana Feldman; Andre Goy; David F Claxton; Spencer Henick Bachow; Gurbakhash Kaur; Jakub Svoboda; Sunita Dwivedy Nasta; David Porter; Daniel J Landsburg; Stephen J Schuster; Bruce D Cheson; Pavel Kiselev; Andrew M Evens Journal: Blood Date: 2016-09-06 Impact factor: 22.113
Authors: Jennifer A Woyach; Richard R Furman; Ta-Ming Liu; Hatice Gulcin Ozer; Marc Zapatka; Amy S Ruppert; Ling Xue; Daniel Hsieh-Hsin Li; Susanne M Steggerda; Matthias Versele; Sandeep S Dave; Jenny Zhang; Ayse Selen Yilmaz; Samantha M Jaglowski; Kristie A Blum; Arletta Lozanski; Gerard Lozanski; Danelle F James; Jacqueline C Barrientos; Peter Lichter; Stephan Stilgenbauer; Joseph J Buggy; Betty Y Chang; Amy J Johnson; John C Byrd Journal: N Engl J Med Date: 2014-05-28 Impact factor: 91.245
Authors: Dan A Landau; Scott L Carter; Petar Stojanov; Aaron McKenna; Kristen Stevenson; Michael S Lawrence; Carrie Sougnez; Chip Stewart; Andrey Sivachenko; Lili Wang; Youzhong Wan; Wandi Zhang; Sachet A Shukla; Alexander Vartanov; Stacey M Fernandes; Gordon Saksena; Kristian Cibulskis; Bethany Tesar; Stacey Gabriel; Nir Hacohen; Matthew Meyerson; Eric S Lander; Donna Neuberg; Jennifer R Brown; Gad Getz; Catherine J Wu Journal: Cell Date: 2013-02-14 Impact factor: 41.582
Authors: Dan A Landau; Eugen Tausch; Amaro N Taylor-Weiner; Chip Stewart; Johannes G Reiter; Jasmin Bahlo; Sandra Kluth; Ivana Bozic; Mike Lawrence; Sebastian Böttcher; Scott L Carter; Kristian Cibulskis; Daniel Mertens; Carrie L Sougnez; Mara Rosenberg; Julian M Hess; Jennifer Edelmann; Sabrina Kless; Michael Kneba; Matthias Ritgen; Anna Fink; Kirsten Fischer; Stacey Gabriel; Eric S Lander; Martin A Nowak; Hartmut Döhner; Michael Hallek; Donna Neuberg; Gad Getz; Stephan Stilgenbauer; Catherine J Wu Journal: Nature Date: 2015-10-14 Impact factor: 49.962
Authors: Jan A Burger; Dan A Landau; Amaro Taylor-Weiner; Ivana Bozic; Huidan Zhang; Kristopher Sarosiek; Lili Wang; Chip Stewart; Jean Fan; Julia Hoellenriegel; Mariela Sivina; Adrian M Dubuc; Cameron Fraser; Yulong Han; Shuqiang Li; Kenneth J Livak; Lihua Zou; Youzhong Wan; Sergej Konoplev; Carrie Sougnez; Jennifer R Brown; Lynne V Abruzzo; Scott L Carter; Michael J Keating; Matthew S Davids; William G Wierda; Kristian Cibulskis; Thorsten Zenz; Lillian Werner; Paola Dal Cin; Peter Kharchencko; Donna Neuberg; Hagop Kantarjian; Eric Lander; Stacey Gabriel; Susan O'Brien; Anthony Letai; David A Weitz; Martin A Nowak; Gad Getz; Catherine J Wu Journal: Nat Commun Date: 2016-05-20 Impact factor: 14.919
Authors: Shruti Sharma; Natalie Galanina; Ailin Guo; Jimmy Lee; Sabah Kadri; Charles Van Slambrouck; Bradley Long; Weige Wang; Mei Ming; Larissa V Furtado; Jeremy P Segal; Wendy Stock; Girish Venkataraman; Wei-Jen Tang; Pin Lu; Yue Lynn Wang Journal: Oncotarget Date: 2016-10-18
Authors: Michael Y Choi; George F Widhopf; Emanuela M Ghia; Reilly L Kidwell; Md Kamrul Hasan; Jian Yu; Laura Z Rassenti; Liguang Chen; Yun Chen; Emily Pittman; Minya Pu; Karen Messer; Charles E Prussak; Januario E Castro; Catriona Jamieson; Thomas J Kipps Journal: Cell Stem Cell Date: 2018-06-01 Impact factor: 24.633
Authors: AnnaLynn M Williams; Andrea M Baran; Carla Casulo; Patrick Reagan; Jonathan W Friedberg; Margaret Helber; Jeremiah Moore; Elizabeth Baloga; Clive S Zent; Paul M Barr Journal: Clin Lymphoma Myeloma Leuk Date: 2018-10-13
Authors: John C Byrd; William G Wierda; Anna Schuh; Stephen Devereux; Jorge M Chaves; Jennifer R Brown; Peter Hillmen; Peter Martin; Farrukh T Awan; Deborah M Stephens; Paolo Ghia; Jacqueline Barrientos; John M Pagel; Jennifer A Woyach; Kathleen Burke; Todd Covey; Michael Gulrajani; Ahmed Hamdy; Raquel Izumi; Melanie M Frigault; Priti Patel; Wayne Rothbaum; Min Hui Wang; Susan O'Brien; Richard R Furman Journal: Blood Date: 2020-04-09 Impact factor: 22.113
Authors: James I Barnes; Vasu Divi; Adrian Begaye; Russell Wong; Steven Coutre; Douglas K Owens; Jeremy D Goldhaber-Fiebert Journal: Blood Adv Date: 2018-08-14
Authors: Paul J Hampel; Hua-Jay J Cherng; Timothy G Call; Wei Ding; Mahsa Khanlari; Ellen D McPhail; Roberto N Miranda; Pei Lin; Hussein A Tawbi; Alessandra Ferrajoli; William G Wierda; Nitin Jain; Sameer A Parikh Journal: Blood Adv Date: 2020-09-22
Authors: Paul J Hampel; Timothy G Call; Kari G Rabe; Wei Ding; Eli Muchtar; Saad S Kenderian; Yucai Wang; Jose F Leis; Thomas E Witzig; Amber B Koehler; Amie L Fonder; Susan M Schwager; Daniel L Van Dyke; Esteban Braggio; Susan L Slager; Neil E Kay; Sameer A Parikh Journal: Oncologist Date: 2020-09-20
Authors: Kallesh D Jayappa; Craig A Portell; Vicki L Gordon; Brian J Capaldo; Stefan Bekiranov; Mark J Axelrod; L Kyle Brett; Julia D Wulfkuhle; Rosa I Gallagher; Emanuel F Petricoin; Timothy P Bender; Michael E Williams; Michael J Weber Journal: Blood Adv Date: 2017-06-13